TY PHAR.(SZ:002728) Zheng Quan Zhi Xing·2025-08-15 16:24Core Viewpoint - Dongguan Securities has conducted a thorough review of the temporary use of idle funds raised by Te Yi Pharmaceutical Group Co., Ltd. through a simplified procedure for issuing shares to specific targets in 2023, confirming compliance with relevant regulations and the necessity of the fund usage [1][7][8] Fundraising Basic Situation - Te Yi Pharmaceutical received approval from the China Securities Regulatory Commission on September 4, 2023, to issue shares, raising a net amount of approximately RMB 268.89 million after deducting issuance costs [1] - The funds have been fully received and verified by Da Xin Accounting Firm on September 15, 2023 [1] Fund Usage and Idle Reasons - As of June 30, 2025, the company has utilized RMB 60 million of the raised funds, leaving a balance of RMB 210.48 million, which includes net interest income [2] - The idle funds are primarily due to the construction cycle required for the modernization of traditional Chinese medicine product lines and technology upgrades [3] Previous Use of Idle Funds - On December 26, 2024, the company’s board approved the temporary use of up to RMB 200 million of idle funds for working capital, which has since been fully returned to the dedicated fundraising account by July 2, 2025 [4][5] Current Proposal for Idle Funds - The company plans to temporarily use up to RMB 100 million (37.19% of the net amount raised) of idle funds for working capital, with a repayment period not exceeding 12 months [5][7] - This usage aims to enhance fund efficiency, reduce financial costs, and maintain the interests of the company and its shareholders [6][8] Review and Approval Process - The board has approved the plan to use idle funds, ensuring compliance with relevant regulations and confirming that it will not affect the implementation of original fundraising projects [7][8]